Under the agreement, Clinical Data, acting as the study sponsor, will apply metabolomics analysis to serum samples from a population of patients diagnosed with lung cancer and matched control subjects without lung cancer recruited as part of the National Cancer Institute (NCI) -funded Specialized Program of Research Excellence (SPORE) in Lung Cancer at the UPCI. The serum samples will be provided to Clinical Data by the UPCI.
Israel M. Stein, MD, President and Chief Executive Officer of Clinical Data, said, "This is an important collaboration for Clinical Data and could generate new insight into the applicable pharmacogenomics of a diverse patient population afflicted with lung cancer."
"In essence, this collaboration supports a pilot study to determine the suitability of metabolomics for cancer detection and screening."
"We anticipate that the data created by this study may demonstrate the robustness of our metabolomics platform to both research partners and potential customers."
"The field of metabolomics offers tremendous promise for patients and the drug industry alike. We know that Clinical Data possesses one of the most robust metabolomics platforms and analytical skill sets in this industry."
"We anticipate that the results of this analysis may yield a strong case for commercialization within the lung cancer application."
The Company notes that any new intellectual property or inventions that are derived from this study will remain the property of the respective party that makes any new discovery with final ownership determined by applicable U.S. Patent Law.